The Dermatology Digest

DECEMBER 18, 2024

Food and Drug Administration (FDA) has approved STEQEYMA (ustekinumab-stba), a biosimilar to STELARA (ustekinumab), for subcutaneous injection or intravenous infusion in adult and pediatric patients with plaque psoriasis and psoriatic arthritis, as well as adult patients with Crohn’s disease and ulcerative colitis. immunology market.”

Portfolios 69

Portfolios Injections Office Safety 69

AAAMS

APRIL 18, 2024

Introduction to Injectable Training Courses Injectable training courses are your fastest ticket from being a beginner to a pro in the cosmetic industry. The journey starts with understanding what injectables are – substances like Botox and fillers that enhance facial features and diminish and promote a youthful appearance.

Injections 40

Injections Training Legal Facials 40

The Dermatology Digest

SEPTEMBER 9, 2024

It incorporates Polyglutamic Acid (PGA), a peptide known for its hydrating properties The non-injectable Elastiderm Advanced Filler Concentrate is formulated with Acetyl Hexapeptide-1, to smooth wrinkles and add volume.

Portfolios 36

Portfolios Dermatology Injections Marketing 36

The Dermatology Digest

APRIL 1, 2024

“There remains a significant need for new, innovative treatment for vitiligo and other immune-mediated dermatologic conditions, and we look forward to working together with the CMS team to bringing these products to market in China.” The transaction is effective immediately upon the execution of the Collaboration and License Agreement.

Portfolios 36

Portfolios Injections Innovations Sales 36

AAAMS

FEBRUARY 22, 2023

You’ll Enter a Hot Market The global market for medical aesthetics is booming. Driven by pandemic-related trends that have normalized virtual work environments, market analysts are documenting record-breaking demand for aesthetic procedures. The market forecast for medical aesthetics has a projected 2027 value of $23.4

Work-Life Balance 52

Work-Life Balance Training Office Marketing 52

The Dermatology Digest

OCTOBER 1, 2024

Food and Drug Administration (FDA) are aligned on the regulatory pathway for ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX (onabotulinumtoxinA) as the reference product. market for all of BOTOX’s currently approved and future therapeutic indications under a single approval.”

Hydration 36

Hydration Portfolios Office Surgery 36

Aesthetics Advisor

SEPTEMBER 15, 2023

Moreover, Glenmark Pharmaceuticals received manufacturing and marketing approval for the Nitric Oxide Nasal Spray (NONS) as part of an accelerated approval process. This is clinically relevant for the use of Carragelose-containing products: The marketed nasal sprays have a Carragelose concentration of 1.2 the South-African or B.1.351,

Hospital 69

Hospital Clinic Marketing Medical 69